Basal Cell Carcinoma clinical trials at UCSF

2 in progress, 1 open to eligible people

Basal cell carcinoma is a skin cancer that usually appears in sun-exposed areas. UCSF is testing a medicine named RP1 in patients who have had a solid organ transplant. RP1 is being studied to measure its effectiveness in treating advanced cases of basal cell carcinoma.

Showing trials for

  • RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies

    open to eligible people ages 18 years and up

    This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malignancies. The study will enroll a total of 65 evaluable patients. Patients will participate up to approximately 3 years including a 28-day screening period, up to approximately 1 year treatment period, and a 2-year follow-up period.

    San Francisco, California and other locations

  • Beta-only IL-2 ImmunoTherapY Study

    Sorry, not currently recruiting here

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    San Francisco, California and other locations

Last updated: